Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
Portfolio Pulse from Vandana Singh
Genfit SA and Ipsen SA announced topline results from the Phase III ELATIVE trial of elafibranor in primary biliary cholangitis (PBC), meeting its primary composite endpoint. However, CymaBay Therapeutics' ongoing Phase 3 RESPONSE study is expected to show a statistically significant reduction in itch with its drug, seladelpar. This has led to optimism for CymaBay's stock, with an Outperform rating maintained by a William Blair analyst.
June 30, 2023 | 6:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay's ongoing Phase 3 RESPONSE study is expected to show a statistically significant reduction in itch with its drug, seladelpar, leading to optimism for its stock.
The positive anticipation for the results of CymaBay's ongoing Phase 3 RESPONSE study, along with the maintained Outperform rating by a William Blair analyst, is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Genfit SA announced topline results from the Phase III ELATIVE trial of elafibranor in primary biliary cholangitis (PBC), meeting its primary composite endpoint.
The positive results from the Phase III ELATIVE trial of elafibranor in PBC could potentially boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Ipsen SA announced topline results from the Phase III ELATIVE trial of elafibranor in primary biliary cholangitis (PBC), meeting its primary composite endpoint.
The positive results from the Phase III ELATIVE trial of elafibranor in PBC could potentially boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50